Eribulin
Back to searchMolecule Structure
Scientific Name
Eribulin
Description of the Drug
Eribulin is a microtubule inhibitor used to treat metastatic breast cancer and metastatic or unresectable liposarcoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08871
http://www.drugbank.ca/drugs/DB08871
Brand Name(s)
Halaven
Company Owner(s)
Eisai Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tubulin | PROTEIN COMPLEX GROUP | INHIBITOR | CHEMBL2095182 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15783821 | ||
| DrugBank | DB08871 | ||
| PubChem: Thomson Pharma | 16446284 | ||
| PubChem | 11354606 | ||
| PDBe | 6K9 | ||
| DrugCentral | 4171 | ||
| ChemicalBook | CB22546700 | ||
| Guide to Pharmacology | 6813 | ||
| rxnorm | ERIBULIN MESYLATE | HALAVEN | ERIBULIN |
| ChEBI | 63587 | ||
| ZINC | ZINC000169344691 |
